四重暴露/难治性多发性骨髓瘤:既往接受过抗 CD38、IMiDs、蛋白酶体抑制剂与 BCMA 靶向治疗的患者 Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies. PubMed 2026/05/06 发表Clin Lymphoma Myeloma LeukQ1 · IF 4.1(JCR 2025) 靶点:CD38靶点:BCMA多发性骨髓瘤淋巴瘤白血病地区:欧洲
靶向 CD19 CAR-T 细胞治疗的非 ICANS 神经毒性与运动及神经认知治疗中出现的不良事件:一例病例报告 Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case PubMed 2026/02/16 发表Front ImmunolQ1 · IF 7(JCR 2025) 靶点:CD19靶点:CD38靶点:BCMA技术:CAR-T弥漫大B细胞淋巴瘤多发性骨髓瘤淋巴瘤
双特异性抗体在多发性骨髓瘤中的演进 The evolution of bispecific antibodies in multiple myeloma. PubMed 2026/02/01 发表Chin Clin OncolQ3 · IF 2.7(JCR 2025) 靶点:CD20靶点:CD38靶点:BCMA技术:双特异性抗体多发性骨髓瘤B细胞淋巴瘤淋巴瘤
SOHO 最新进展与后续问题 | 骨髓瘤早期复发的治疗:非 CAR-T 细胞 SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell. PubMed 2025/10/04 发表Clin Lymphoma Myeloma LeukQ1 · IF 4.1(JCR 2025) 靶点:CD38靶点:BCMA靶点:GPRC5D技术:CAR-T技术:双特异性抗体多发性骨髓瘤淋巴瘤白血病
拓宽视野:CAR-T 细胞在当前适应证之外的潜在应用 Broadening the horizon: potential applications of CAR-T cells beyond current indications. PubMed 2023/11/27 发表Front ImmunolQ1 · IF 7(JCR 2025) 靶点:CD30靶点:CD38靶点:BCMA技术:CAR-T弥漫大B细胞淋巴瘤急性淋巴细胞白血病慢性淋巴细胞白血病